| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Anam Qudrat | |
| Netra Unni | |||
| P2860 | cites work | Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update | Q22252904 |
| Altering the tropism of lentiviral vectors through pseudotyping | Q24538987 | ||
| Lentiviral vectors in gene therapy: their current status and future potential | Q24629462 | ||
| Lentiviral vector gene therapy: effective and safe? | Q24630888 | ||
| alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies | Q24653247 | ||
| Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons | Q24654644 | ||
| A fluorescent cassette-based strategy for engineering multiple domain fusion proteins | Q24793963 | ||
| The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery | Q24804110 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease | Q28304068 | ||
| AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial | Q28307713 | ||
| Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder | Q28392275 | ||
| Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity | Q28394667 | ||
| The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease | Q28579398 | ||
| Physiology of microglia | Q29547414 | ||
| A third-generation lentivirus vector with a conditional packaging system | Q29616120 | ||
| Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease | Q30493249 | ||
| Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. | Q33226010 | ||
| Bone-marrow-derived microglia: myth or reality? | Q33335604 | ||
| Safety and tolerability of putaminal AADC gene therapy for Parkinson disease | Q33731687 | ||
| Differentiation of mouse bone marrow derived stem cells toward microglia-like cells. | Q33997746 | ||
| Changes in cytokines and neurotrophins in Parkinson's disease | Q34155171 | ||
| Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease | Q34366768 | ||
| Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. | Q34397099 | ||
| Advances in gene therapy for movement disorders. | Q34656049 | ||
| Results from a phase I safety trial of hAADC gene therapy for Parkinson disease | Q34656075 | ||
| PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model | Q34667239 | ||
| Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson's disease | Q34826133 | ||
| The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease | Q49059789 | ||
| Insulin-like growth factor-1 inhibits 6-hydroxydopamine-mediated endoplasmic reticulum stress-induced apoptosis via regulation of heme oxygenase-1 and Nrf2 expression in PC12 cells. | Q53371634 | ||
| Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. | Q55050091 | ||
| Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? | Q64869637 | ||
| Liver growth factor promotes the survival of grafted neural stem cells in a rat model of Parkinson's disease | Q83055130 | ||
| Fibroblast growth factor 20 (FGF20) gene polymorphism and risk of Parkinson's disease: a meta-analysis | Q88104960 | ||
| Progress and problems with the use of viral vectors for gene therapy | Q35120176 | ||
| Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease | Q35161892 | ||
| The role of alpha-synuclein in Parkinson's disease: insights from animal models | Q35209957 | ||
| Current advances in retroviral gene therapy | Q35237554 | ||
| Monocyte-to-macrophage differentiation: synthesis and secretion of a complex extracellular matrix | Q35922338 | ||
| Viral gene therapy strategies: from basic science to clinical application | Q36346137 | ||
| Current advances in using neurotrophic factors to treat neurodegenerative disorders | Q36525034 | ||
| Recent molecular approaches to understanding astrocyte function in vivo | Q37412106 | ||
| Α-synuclein misfolding and Parkinson's disease | Q37949158 | ||
| Microglia: new roles for the synaptic stripper. | Q38073391 | ||
| Innate immune activation in neurodegenerative disease | Q38223011 | ||
| The human nerve growth factor gene: structure of the promoter region and expression in L929 fibroblasts | Q38326441 | ||
| Structural and functional identification of regulatory regions and cis elements surrounding the nerve growth factor gene promoter | Q38333231 | ||
| Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients | Q38465589 | ||
| Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors | Q38886667 | ||
| Desmin-regulated lentiviral vectors for skeletal muscle gene transfer | Q39644545 | ||
| Parkinson's disease and growth factors - are they the answer? | Q39746950 | ||
| Neuronal regulation by which microglia enhance the production of neurotrophic factors for GABAergic, catecholaminergic, and cholinergic neurons | Q40141093 | ||
| Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death | Q40405034 | ||
| Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses | Q40413612 | ||
| Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins | Q40583034 | ||
| Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease | Q40763402 | ||
| Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ. | Q40764405 | ||
| Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease | Q40846012 | ||
| Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease | Q40904090 | ||
| Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial | Q41681737 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Cell-based therapeutics: the next pillar of medicine | Q42613853 | ||
| Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial | Q42650874 | ||
| Parkinson's disease and systemic inflammation | Q42651923 | ||
| Immunity and inflammation in neurodegenerative diseases | Q43104143 | ||
| Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters | Q43233656 | ||
| Neurotrophin secretion from cultured microglia | Q43700685 | ||
| Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. | Q43906992 | ||
| Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. | Q43940184 | ||
| Lentiviral gene transfer to the nonhuman primate brain | Q44028201 | ||
| The delivery of tyrosine hydroxylase accelerates the neurorestoration of Macaca Rhesus model of Parkinson's disease provided by Neurturin | Q44480739 | ||
| Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population | Q45073558 | ||
| Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons | Q46460358 | ||
| Generation of a alpha-synuclein-based rat model of Parkinson's disease | Q46723409 | ||
| Fibroblast growth factor 20 polymorphism in sporadic Parkinson's disease in Northern Han Chinese | Q47796288 | ||
| Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease | Q48132256 | ||
| Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease | Q48254128 | ||
| Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease | Q48289983 | ||
| Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease | Q48297147 | ||
| Metallothionein, neurotrophins and selegiline in providing neuroprotection in Parkinson's disease. | Q48347182 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| Parkinson's disease | Q11085 | ||
| peptide | Q172847 | ||
| nerve tissue protein | Q6996861 | ||
| nerve growth factors | Q98072643 | ||
| P304 | page(s) | 215-25 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | Yale Journal of Biology and Medicine | Q15709982 |
| P1476 | title | Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease | |
| P478 | volume | 89 |
| Q59136331 | Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease | cites work | P2860 |
Search more.